open_access_logo.gif
Personalized Medicine
Future Medicine Ltd. (2004-)
ISSN: 1741-0541 (1744-828X)
Pharmacology & Pharmacy - Pharmacology - Molecular Medicine

APC Discount

No deal has been made for authors affiliated with VU/VUMC to (partly) waive Article Processing Charges.
Deals are available for RUG/UMCG and UU/UMC Utrecht staff.More information on Open Access publishing

Metrics

JCR Science Citation Index (2022)

Impact factor: 2.3
Q3 (Pharmacology & Pharmacy (200/278))

Scopus Journal Metrics (2022)

SJR: 0.358
SNIP: 0.415
CiteScore: 3.1
Rank within the category: Pharmacology, Toxicology and Pharmaceutics - Pharmacology
Quartile: Q3
CiteScore percentile: 35%
CiteScore rank: 196 out of 301
Rank within the category: Biochemistry, Genetics and Molecular Biology - Molecular Medicine
Quartile: Q4
CiteScore percentile: 24%
CiteScore rank: 130 out of 171

Green Open Access

You Share, We Take Care!

Dutch copyright law (art. 25fa Auteurswet) allows you to deposit the publishers’ version (PDF) of short academic work in the university repository six months after the first (online) publication. The VU University Library can now support VU researchers who want to make their publications accessible in the VU Research Portal. If you have an employment contract with VU the library can automatically deposit published PDF-versions (Version of Record) of your academic publications on your behalf in the VU Research Portal.
Interested ? Read all about participation here

Sherpa/Romeo info
Official publisher policy

Sherpa Romeo information is accurate to the best of our knowledge but should not be relied upon for legal advice. (Last modified on: {{item.system_metadata.date_modified}})
For most accurate information, visit the Journal Home Page

Open Access pathways permitted by this journal's policy are listed below by article version.
Click on a pathway for a more detailed view.

  • Prerequisite: {{phrase.phrase}}.
  • Prerequisite for funders: , {{name.name}}.
  • No additional fee for OA publishing via this route.
  • There is an additional fee for OA publishing via this route.
  • There is a {{permission.embargo.amount}} {{permission.embargo.units}} embargo period for OA publishing via this route.
  • There is no embargo period for OA publishing via this route.
  • Copyright is owned by {{permission.copyright_owner}} when publishing via this route.
  • License: {{phrase.phrase}} {{license.version}}
  • Publisher deposit: {{name.name}}
  • Note: {{note}}
Can be published on:
  • {{ location.phrase }} in this list: , {{repo}}.
Conditions:
  • {{condition}}.
  • Prerequisite: {{phrase.phrase}}.
  • Prerequisite for funders: , {{name.name}}.
  • No additional fee for OA publishing via this route.
  • There is an additional fee for OA publishing via this route.
  • There is a {{permission.embargo.amount}} {{permission.embargo.units}} embargo period for OA publishing via this route.
  • There is no embargo period for OA publishing via this route.
  • Copyright is owned by {{permission.copyright_owner}} when publishing via this route.
  • License: {{phrase.phrase}} {{license.version}}
  • Publisher deposit: {{name.name}}
  • Note: {{note}}
Can be published on:
  • {{ location.phrase }} in this list: , {{repo}}.
Conditions:
  • {{condition}}.
  • Prerequisite: {{phrase.phrase}}.
  • Prerequisite for funders: , {{name.name}}.
  • No additional fee for OA publishing via this route.
  • There is an additional fee for OA publishing via this route.
  • There is a {{permission.embargo.amount}} {{permission.embargo.units}} embargo period for OA publishing via this route.
  • There is no embargo period for OA publishing via this route.
  • Copyright is owned by {{permission.copyright_owner}} when publishing via this route.
  • License: {{phrase.phrase}} {{license.version}}
  • Publisher deposit: {{name.name}}
  • Note: {{note}}
Can be published on:
  • {{ location.phrase }} in this list: , {{repo}}.
Conditions:
  • {{condition}}.

Recent Articles In: {{toc.journal.substring(17,toc.journal.length)}}